🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT07655817
Recruiting Phase 2/3

Oral Versus Intravenous Magnesium on Emergence Delirium

NCT07655817 · tracked via the Priya Life Science Egypt tracker
Phase
Phase 2/3
Started
2026-07-01
Last updated
2026-07-06

Condition(s) studied

MagnesiumEmergence DeliriumChildrenAdenotonsillectomy

Investigational drug(s) / intervention(s)

Magnesium glycinateMagnesium sulfate injection →Oral juice and intravenous saline

Magnesium glycinate: cases will receive preoperative oral magnesium dose of 150 mg (10 ml of Magnesium Glycinate Liquid Trace syrup) at two hours before surgery, and will receive intraoperative IV (10 ml) of saline 0.9% over 10 minutes (1ml/min) after induction of anesthesia and before the start of surgical procedure.

Magnesium sulfate injection: cases will receive oral lemon juice (10 ml) at two hours before surgery, and will receive intraoperative IV magnesium sulfate dose of 30 mg/kg (diluted in saline to a total volume of 10 ml) over 10 minutes (1ml/min) after induction of anesthesia and before the start of surgical procedure.

Oral juice and intravenous saline: cases will receive oral lemon juice (10 ml) at two hours before surgery and will receive intraoperative IV (10 ml) of saline 0.9% over 10 minutes (1ml/min) after induction of anesthesia and before the start of surgical procedure.

Study summary

This prospective randomized controlled study will be conducted to compare the effects of preoperative oral magnesium and intraoperative IV magnesium on the incidence and severity of emergence delirium in children undergoing adenotonsillectomy using sevoflurane anesthesia.

Eligibility

Sex
ALL
Min age
4 Years
Max age
7 Years
Healthy volunteers
No
Inclusion Criteria: * Children aged 4 to 7 years * American Society of Anesthesiologist (ASA) Status I or II * Planned for an adenotonsillectomy procedure under sevoflurane general anesthesia. Exclusion Criteria: * Parents declined to participate in the trial * Behavioral changes, neurological or psychiatric problems * Anticonvulsant or sedative drugs * Physical or developmental abnormalities * Allergies to magnesium * cardiovascular, renal, bone, or gastrointestinal diseases.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Tanta University Hospitals Tanta Gharbia Governorate Recruiting

More Tanta University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07655817 on ClinicalTrials.gov ↗ ← All trials in Egypt